1. Home
  2. TYG vs CTNM Comparison

TYG vs CTNM Comparison

Compare TYG & CTNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TYG
  • CTNM
  • Stock Information
  • Founded
  • TYG 2003
  • CTNM 2009
  • Country
  • TYG United States
  • CTNM United States
  • Employees
  • TYG N/A
  • CTNM N/A
  • Industry
  • TYG Investment Managers
  • CTNM
  • Sector
  • TYG Finance
  • CTNM
  • Exchange
  • TYG Nasdaq
  • CTNM Nasdaq
  • Market Cap
  • TYG 469.7M
  • CTNM 377.6M
  • IPO Year
  • TYG N/A
  • CTNM 2024
  • Fundamental
  • Price
  • TYG $48.40
  • CTNM $11.28
  • Analyst Decision
  • TYG
  • CTNM Strong Buy
  • Analyst Count
  • TYG 0
  • CTNM 4
  • Target Price
  • TYG N/A
  • CTNM $29.25
  • AVG Volume (30 Days)
  • TYG 111.5K
  • CTNM 135.4K
  • Earning Date
  • TYG 01-01-0001
  • CTNM 02-16-2025
  • Dividend Yield
  • TYG 6.92%
  • CTNM N/A
  • EPS Growth
  • TYG N/A
  • CTNM N/A
  • EPS
  • TYG 9.77
  • CTNM N/A
  • Revenue
  • TYG $13,618,248.00
  • CTNM N/A
  • Revenue This Year
  • TYG N/A
  • CTNM N/A
  • Revenue Next Year
  • TYG N/A
  • CTNM N/A
  • P/E Ratio
  • TYG $4.81
  • CTNM N/A
  • Revenue Growth
  • TYG N/A
  • CTNM N/A
  • 52 Week Low
  • TYG $28.31
  • CTNM $11.38
  • 52 Week High
  • TYG $48.48
  • CTNM $22.00
  • Technical
  • Relative Strength Index (RSI)
  • TYG 76.97
  • CTNM N/A
  • Support Level
  • TYG $43.56
  • CTNM N/A
  • Resistance Level
  • TYG $44.75
  • CTNM N/A
  • Average True Range (ATR)
  • TYG 0.93
  • CTNM 0.00
  • MACD
  • TYG 0.55
  • CTNM 0.00
  • Stochastic Oscillator
  • TYG 98.91
  • CTNM 0.00

About TYG Tortoise Energy Infrastructure Corporation

Tortoise Energy Infrastructure Corp seeks to provide a high level of current income to stockholders. It invests in fixed-income and dividend-paying equity securities of power and energy infrastructure companies that provide stable and defensive characteristics throughout economic cycles.

About CTNM Contineum Therapeutics Inc. Class A Common Stock

Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.

Share on Social Networks: